Photo : Eftychia Koumarianou and Cyril Berthet, a smooth transition within our pharmaco-imaging and molecular radiotherapy department
We announce the appointment of Dr Eftychia Koumarianou as head of its pharmaco-imaging and molecular radiotherapy (MRT) department.
Oncodesign Services has over 25 years of experience in preclinical oncology and always been a pioneer in exploring new possibilities and technologies. Pharmaco-imaging, a non-invasive approach to support proof of concept in pharmacology is an important activity for us. For a few years, Oncodesign Services has launched a specific department under the leadership of Dr Cyril Berthet to better support customer programs with high level of expertise in nuclear medicine and theragnostic proof of concept. This team is at the heart of our offer DRIVE-MRT, a premium ‘nuclear medicine’ solution in oncology.
Dr Eftychia Koumarianou will succeed to Cyril in a smooth transition to lead this dynamic team. With over 20 years of experience, Eftychia joins us after 4 years as Director of Preclinical & Pharmacy, at the corner of preclinic, regulatory and clinical studies, at ABX-CRO part of the DRIVE-MRT consortium offer. She has a PhD from the University of Athens in Greece and held post-doc positions in POLATOM (Poland), Duke University (North Carolina) and Duke-NUS (Singapore). Last but not least, she contributed to the development and registration of Lutathera® at AAA.
Eftychia Koumarianou, head of pharmaco-imaging department said: “I am thrilled to join this dynamic company and have the opportunity to lead efforts in developing new and innovative services, with a particular focus on oncology. With such a talented team and cutting-edge technology, I am confident that we can make significant strides in improving treatments for cancer patients and making a meaningful impact in the fight against this devastating disease”
Cyril Berthet, COO commented: “Welcome aboard! It’s such an exciting moment to see you join our team. After several years working together on the DRIVE-MRT consortium, I can’t wait to continue the journey. I have no doubt that your expertise and experience will add immense value to our team, and I’m looking forward to the amazing things we’ll achieve together.”
